Depression is one of the significant contributors to the global burden disease, affecting
nearly 264 million people worldwide along with the increasing rate of suicidal deaths …

There is an increasing heavy disease burden of major depressive disorder (MDD) globally.
Both high diagnostic heterogeneity and complicated pathological mechanisms of MDD pose …

With improvements to both scan quality and facial recognition software, there is an
increased risk of participants being identified by a 3D render of their structural neuroimaging …

Importance Social and economic costs of depression are exacerbated by prolonged periods
spent identifying treatments that would be effective for a particular patient. Thus, a tool that …

Cytochrome P450 drug-metabolizing enzymes may contribute to interindividual differences
in antidepressant outcomes. We investigated the effects of CYP2C19 and CYP2D6 gene …

Antidepressant outcomes in older adults with depression is poor, possibly because of
comorbidities such as cerebrovascular disease. Therefore, we leveraged multiple genome …

Studies of clinical populations that combine MRI data generated at multiple sites are
increasingly common. The Canadian Biomarker Integration Network in Depression (CAN …

Anhedonia is thought to reflect deficits in reward processing that are associated with
abnormal activity in mesocorticolimbic brain regions. It is expressed clinically as a deficit in …

Abstract Treatment outcomes widely vary for individuals diagnosed with major depressive
disorder, implicating a need for deeper understanding of the biological mechanisms …

One of the biggest challenges in treating depression is the heterogeneous and qualitative
nature of its clinical presentations. This highlights the need to find quantitative molecular …